We use cookies to help us improve the website and your experience using it. You may delete and block all cookies from this site at any time. However, please note this may result in parts of the site no longer working correctly. If you continue without changing your settings we will assume you are happy to receive all cookies on this site.

Close

New partnership boosts children's research at CMFT

Children's research at the NIHR / Wellcome Trust Manchester Clinical Research Facility boosted through new partnership with PPD.

Central Manchester University Hospitals NHS Foundation Trust (CMFT) has formalised its relationship with Pharmaceutical Product Development, LLC (PPD), with the clinical research facility becoming part of an international paediatric investigator network and affirming its commitment to paediatric research.

Through the network, CMFT aims to attract additional paediatric studies and provide participation in research as a treatment option for more children with rare diseases.  The benefits of taking part in research for patients and their families can include a better understanding of their condition, and improved health outcomes for them and/or future patients.

The  NIHR / Wellcome Trust Manchester Clinical Research Facility (CRF) at the Royal Manchester Children's Hospital was the first specialist facility in the North West and one of only a small handful across the UK.  The CRF, which also operates an adult's facility on Grafton Street, offers state-of-the-art equipment and facilities and has a team of specialist research nurses and support staff.

Helen Pidd, Operations Director at the CRF said, "Many patients cared for by our children's CRF suffer from complex health conditions, for which there are no treatments currently available.  This is an exciting opportunity to provide further opportunities for these patients to receive cutting edge treatments."

The paediatric investigator network-which includes seven other world-renowned centres of excellence among its members-will also provide biopharmaceutical companies with faster trial start up, more predictable patient enrolment and higher-quality data.

Read PPD's press release.

childrens research